

# The Journal of PHARMACOLOGY

## And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

April 2024

Vol. 389, No. 1

### Contents

#### VIEWPOINT

- A Statement on the Pharmacology of Reinstatement: Naltrexone and Relapse to Opioid Seeking 1  
*James E. Barrett*
- The Effects of Chronic Naltrexone on Reinstatement of Opioid-Induced Drug-Seeking Behavior and Antinociception 5  
*Sarah L. Withey, Jack Bergman, and Carol A. Paronis*

#### VIEWPOINT

- Label-Free Dynamic Mass Redistribution Assay To Characterize Holistic Chemokine Receptor Pharmacology in Neutrophils 15  
*Alex R.B. Thomsen*
- ☐ The Neutrophil Dynamic Mass Redistribution Assay as a Medium throughput Primary Cell Screening Assay 19  
*Lisa A. Stott, Armand Drieu la Rochelle, Susan Brown, Greg Osborne, Catherine J. Hutchings, Simon Poulter, Kirstie A. Bennett, and Matt Barnes*

#### EDITORIAL

- Obituary: Travis Thompson—Editorial 32  
*Michael A. Nader, Mark Egli, and Jack Henningfield*

#### CARDIOVASCULAR

- Endothelial Extracellular Vesicles Enriched in microRNA-34a Predict New-Onset Diabetes in Coronavirus Disease 2019 (COVID-19) Patients: Novel Insights for Long COVID Metabolic Sequelae 34  
*Pasquale Mone, Stanislovas S. Jankauskas, Maria Virginia Manzi, Jessica Gambardella, Antonietta Coppola, Urna Kansakar, Raffaele Izzo, Giuseppe Fiorentino, Angela Lombardi, Fahimeh Varzideh, Daniela Sorriento, Bruno Trimarco, and Gaetano Santulli*

#### CELLULAR AND MOLECULAR

- ☐ N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia 40  
*Mia P. Sams, James Iansavitchous, Madeline Astridge, Heidi Rysan, Li S. Xu, Bruno Rodrigues de Oliveira, and Rodney P. DeKoter*

#### CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

- ☐ Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtubule Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo 51  
*Daniel P. Radin, Sophie Shifman, Ian R. Outhwaite, Aryan Sharma, Robert Bases, Markus A. Seeliger, and Stella E. Tsirka*

#### DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- ☐ Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease 61  
*David Hollenback, Eva Hambruch, Gero Fink, Manfred Birkel, Andreas Schulz, Martin Hornberger, Kathy Liu, Kelly MacLennan Staiger, Helen Desiree Krol, Ulrich Deuschle, Christoph Steeneck, Olaf Kinzel, John T. Liles, Grant Budas, William J. Watkins, and Claus Kremoser*

#### INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

- Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate 76  
*Masumi Oka, Sohta Akaki, Osamu Ohno, Maho Terasaki, Yuho Hamaoka-Tamura, Michiko Saito, Shinichi Kato, Asuka Inoue, Junken Aoki, Kenji Matsuno, Kazuyuki Furuta, and Satoshi Tanaka*

## METABOLISM, TRANSPORT, AND PHARMACOGENETICS

- ☐ Humanization of *SLCO2B1* in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420 87  
*Marta Rysz, Anima M. Schäfer, Nikolaos Paloumpis, Jonny Kinzi, Karin Brecht, Isabell Seibert, Seraina Schmidlin, Katja In-Albon, Daniel Ricklin, and Henriette E. Meyer zu Schwabedissen*
- ☐ Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability 96  
*Wenqiu Zhang, Ju-Hee Oh, Wenjuan Zhang, Courtney C. Aldrich, Rachael W. Sirianni, and William F. Elmquist*

## NEUROPHARMACOLOGY

- ☐ NCP, a Dual Kappa and mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties 106  
*Peng Huang, Conrad K. Ho, Danni Cao, Saadet Inan, Scott M. Rawls, Mengchu Li, Boshi Huang, Piyusha P. Pagare, E. Andrew Townsend, Justin L. Poklis, Matthew S. Halquist, Matthew Banks, Yan Zhang, and Lee-Yuan Liu-Chen*
- Selective KCNQ2/3 Potassium Channel Opener ICA-069673 Inhibits Excitability in Mouse Vagal Sensory Neurons 118  
*Hui Sun and Bradley J. Udem*

## ERRATUM

- Correction to “The  $\beta$ -Blocker Carvedilol and Related Aryloxypropanolamines Promote ERK1/2 Phosphorylation in HEK<sub>293</sub> Cells with  $K_A$  Values Distinct From Their Equilibrium Dissociation Constants as  $\beta_2$ -Adrenoceptor Antagonists: Evidence for Functional Affinity” 128

☐ Supplemental material is available at [jpet.aspetjournals.org](http://jpet.aspetjournals.org).

*About the cover:* Model of disease progression of Mb1-Cre $\Delta$ PB leukemias in mice treated with control drinking water (top) or N-acetylcysteine drinking water (bottom). See the article by Sams et al. ([dx.doi.org/10.1124/jpet.123.002000](https://doi.org/10.1124/jpet.123.002000)).